| Firm |
Analyst |
| B Riley FBR |
David Buck |
| BMO Capital Markets |
Gary Nachman |
| BTIG |
Timothy Chiang |
| Canaccord Genuity |
Dewey Steadman |
| Cantor |
Louise Chen |
| Cowen and Company |
Ken Cacciatore |
| Deutsche Bank |
Gregg Gilbert |
| Goldman Sachs |
Dana Flanders |
| SunTrust Robinson Humphrey |
John Boris |
| J. P. Morgan |
Chris Schott |
| Leerink Partners |
Ami Fadia |
| Morgan Stanley |
David Risinger |
| PiperJaffray |
David Amsellem |
| Raymond James |
Elliot Wilbur |
| RBC Capital Markets |
Randall Stanicky |
Amneal Pharmaceuticals ("Amneal") is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Amneal's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Amneal or its management. Amneal does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.